NEWS
Ocuphire Pharma Announces Acquisition of Opus Genetics
Ocuphire Pharma (Nasdaq: OCUP) has announced the all-stock acquisition of Opus Genetics, creating a leading clinical-stage company focused on gene therapy treatments for rare inherited retinal degenerations. The combined company will be renamed Opus Genetics, Inc. and trade under the ticker symbol IRDeffective October 24, 2024.
Key highlights include:
New OPGx-LCA5 Phase 1/2 6-month data showing visual improvement in 3 out of 3 patients
LYNX-2 and VEGA-3 Phase 3 trials of Phentolamine Ophthalmic Solution 0.75% on track for top-line data in Q1 and H1 2025, respectively
Seeking strategic partner for APX3330 development
Projected cash runway extended into 2026
Four major clinical milestones expected in 2025
Key highlights include:
New OPGx-LCA5 Phase 1/2 6-month data showing visual improvement in 3 out of 3 patients
LYNX-2 and VEGA-3 Phase 3 trials of Phentolamine Ophthalmic Solution 0.75% on track for top-line data in Q1 and H1 2025, respectively
Seeking strategic partner for APX3330 development
Projected cash runway extended into 2026
Four major clinical milestones expected in 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2217Followers
104Following
21KVisitors
Follow